Table 5.
Pharmacologic treatment prior to HSS admission
| Overall | COVID floor admit | COVID ICU admit | Other admit | |
|---|---|---|---|---|
| N | 148 | 111 | 19 | 18 |
| Hydroxychloroquine (%) | 118 (79.7) | 97 (87.4) | 18 (94.7) | 3 (16.7) |
| Azithromycin (%) | 62 (41.9) | 56 (50.5) | 5 (26.3) | 1 (5.6) |
| HTN meds (ACE inhibitors) (%) | 70 (47.3) | 52 (46.8) | 11 (57.9) | 7 (38.9) |
| Corticosteroids (%) | 13 (8.8) | 8 (7.2) | 2 (10.5) | 3 (16.7) |
| Analgesics (NSAIDs) (%) | 52 (35.1) | 31 (27.9) | 11 (57.9) | 10 (55.6) |
| Other (%) | 4 (2.7) | 3 (2.7) | 0 (0.0) | 1 (5.6) |
| None (%) | 28 (18.9) | 13 (11.7) | 2 (10.5) | 13 (72.2) |
ACE angiotensin-converting enzyme, HTN hypertension, NSAID non-steroidal anti-inflammatory drug